Skip to content
Inciteful Med

Life After Treatment: Monitoring and Survivorship

Last updated:

During follicular lymphoma remission, doctors recommend symptom-based monitoring with regular blood work and physical exams instead of routine PET scans. This avoids false positives while effectively tracking your health and managing any late side effects.

Key Takeaways

  • • Routine PET scans are generally not recommended for follicular lymphoma patients in remission without symptoms due to high false-positive rates.
  • • Standard monitoring includes clinical surveillance with regular physical exams, symptom reviews, and complete blood counts.
  • • Late-term side effects of treatments can include weakened immune systems, low white blood cell counts, and rarely, secondary cancers.
  • • Scanxiety is common, but evidence-based approaches like Cognitive Behavioral Therapy can help manage the emotional weight of survivorship.

Reaching remission in follicular lymphoma (FL) is a major milestone, but it often marks the beginning of a new, different kind of challenge. Transitioning from active treatment to survivorship involves shifting your focus from “fighting the cancer” to long-term monitoring and managing the emotional weight of living with a chronic condition [1][2].

The Surveillance Strategy: Less is More

It is natural to want frequent scans to prove the cancer is gone. However, medical guidelines for follicular lymphoma in remission generally advise against routine PET/CT scans for patients who have no symptoms [3][4].

Doctors recommend a “symptom-based” approach for several reasons:

  • High False-Positive Rates: Routine PET/CT scans in healthy-feeling survivors have a false-positive rate as high as 50%. This often leads to unnecessary biopsies, extra radiation, and intense, unneeded stress [3][5].
  • No Survival Benefit: Studies have shown that finding a relapse through a routine scan before a patient feels symptoms does not help them live longer [4][3].
  • Radiation Risk: Repeated CT and PET scans involve ionizing radiation, which can slightly increase the long-term risk of developing other types of cancer [6].

What routine monitoring looks like:
Instead of scans, your follow-up will typically focus on clinical surveillance [7][8]:

  1. Physical Exams: Every 3–6 months initially, checking for enlarged lymph nodes or an enlarged spleen [7].
  2. Blood Work: Regular Complete Blood Counts (CBC) to monitor your white cells, red cells, and platelets [7].
  3. Symptom Review: Discussing any new fatigue, drenching night sweats, or unexplained weight loss [9][10].

Late-Term Toxicities to Watch For

Modern treatments like BR (Bendamustine-Rituximab) and R-CHOP are very effective, but they can have “long tails”—side effects that appear months or even years later [11][12].

  • Secondary Malignancies: A small percentage of survivors may develop therapy-related blood cancers, such as MDS (Myelodysplastic Syndrome) or AML (Acute Myeloid Leukemia) [13][14]. This risk is higher for those who have had multiple rounds of intensive chemotherapy [15][16].
  • Late-Onset Neutropenia: Some patients experience a sudden drop in neutrophils (infection-fighting white blood cells) weeks or months after their last dose of rituximab [17][18].
  • Hypogammaglobulinemia: This is a fancy term for low levels of protective antibodies. It can make you more susceptible to common infections like sinus or lung infections [18][12].
  • Vaccination Importance: Because of lower antibody levels, it is critical to discuss the timing of non-live vaccines (like flu, COVID, or RSV) with your oncologist to ensure your immune system is protected [18].

Managing “Scanxiety” and Emotional Health

Scanxiety—the intense anxiety and dread that occurs before and during follow-up appointments—is incredibly common, affecting nearly half of all follicular lymphoma survivors [2][19].

Because FL is a relapsing-remitting disease, the “wait” can feel like a heavy weight. To manage this psychological burden, consider the following evidence-based approaches:

  • Cognitive Behavioral Therapy (CBT): This type of therapy helps you identify and shift the thought patterns that fuel your fear of the cancer returning [20][21].
  • Acceptance and Commitment Therapy (ACT): ACT focuses on “psychological flexibility”—learning to accept difficult feelings while still taking action toward a meaningful life [22][23].
  • Mindfulness and Peer Support: Connecting with others who share your diagnosis can reduce the feeling of isolation and help you navigate the “new normal” of life after treatment [20][21].

Remember, the goal of survivorship is to live your life as fully as possible. If the fear of recurrence is interfering with your sleep, work, or relationships, it is important to tell your medical team so they can provide the right support [19][24].

Frequently Asked Questions

Why don't I need routine PET scans while in remission for follicular lymphoma?
Routine PET scans in healthy-feeling patients have a high false-positive rate, which can lead to unnecessary biopsies and stress. Studies show that finding a relapse on a scan before symptoms appear does not help patients live longer.
What symptoms should I watch for after follicular lymphoma treatment?
You should monitor for new or unusual fatigue, drenching night sweats, unexplained weight loss, or a new painless lump. Contact your doctor if you experience any of these symptoms between your scheduled oncology visits.
What are the late side effects of follicular lymphoma treatments like R-CHOP or Bendamustine?
Late side effects can include low levels of infection-fighting white blood cells, reduced protective antibodies, and in rare cases, secondary blood cancers. Your doctor will run regular blood tests to check for these issues.
How can I manage anxiety before my follow-up oncology appointments?
Managing 'scanxiety' can involve approaches like Cognitive Behavioral Therapy (CBT) or Acceptance and Commitment Therapy (ACT), which help reframe fearful thoughts. Joining a peer support group can also help reduce feelings of isolation.

Questions for Your Doctor

  • • Since I'm in remission and feeling well, why do we not perform a routine PET/CT scan to 'be sure' the cancer hasn't returned?
  • • What specific symptoms or physical changes should I monitor for that would indicate it’s time to call you between scheduled visits?
  • • What is my risk for late-term side effects like secondary cancers (MDS/AML) or low antibody levels (hypogammaglobulinemia)?
  • • Can we review my most recent blood work? Are my neutrophil and immunoglobulin levels within a healthy range?
  • • If my 'scanxiety' becomes overwhelming, what resources or referrals (like specialized therapy) can you provide to help me manage it?

Questions for You

  • • On a scale of 1-10, how much does the period leading up to my check-ups affect my daily life and sleep?
  • • Have I noticed any small changes in my health, like unusual fatigue or a new, painless lump, that I’ve been dismissing?
  • • Who is my primary support person for medical appointments, and have I shared my monitoring schedule with them?

Want personalized information?

Type your question below to get evidence-based answers tailored to your situation.

References

  1. 1

    Managing Follicular Lymphoma in the Elderly Population.

    Tan JJC, Sze YL, Choong Shi Hui C

    Case reports in medicine 2023; (2023()):1038934 doi:10.1155/2023/1038934.

    PMID: 36643720
  2. 2

    Quality of life and fear of cancer recurrence in patients and survivors of non-Hodgkin lymphoma.

    Ellis S, Brown RF, Thorsteinsson EB, et al.

    Psychology, health & medicine 2022; (27(8)):1649-1660 doi:10.1080/13548506.2021.1913756.

    PMID: 33928815
  3. 3

    Different roles of surveillance positron emission tomography according to the histologic subtype of non-Hodgkin's lymphoma.

    Kim YR, Kim SJ, Cheong JW, et al.

    The Korean journal of internal medicine 2021; (36(Suppl 1)):S245-S252 doi:10.3904/kjim.2019.376.

    PMID: 32550718
  4. 4

    Improvements in Imaging of Hodgkin Lymphoma: Positron Emission Tomography.

    Hutchings M

    Cancer journal (Sudbury, Mass.) 2018; (24(5)):215-222 doi:10.1097/PPO.0000000000000336.

    PMID: 30247256
  5. 5

    Granulomatous Lymphangitis Masquerading as Relapsed Hodgkin Disease on FDG PET/CT.

    Mustafa M, Patel D, Shen L, et al.

    Tomography (Ann Arbor, Mich.) 2018; (4(1)):1-3 doi:10.18383/j.tom.2017.00022.

    PMID: 30042982
  6. 6

    The Role of Whole-Body MRI in Patients with Lymphoma: A Narrative Review.

    Renzetti B, Cattabriga A, Brocchi S, et al.

    Technology in cancer research & treatment 2025; (24()):15330338251359724 doi:10.1177/15330338251359724.

    PMID: 40820493
  7. 7

    Diagnosis, management and follow-up of follicular lymphoma: a consensus practice statement from the Australasian Lymphoma Alliance.

    Tobin JWD, Hapgood G, Johnston A, et al.

    Internal medicine journal 2024; (54(8)):1384-1395 doi:10.1111/imj.16454.

    PMID: 39099075
  8. 8

    Description of late onset neutropenia in indolent lymphoma patients treated with bendamustine plus rituximab.

    Verriere B, Gastaud L, Chamorey E, et al.

    Hematological oncology 2018; (36(1)):144-149 doi:10.1002/hon.2458.

    PMID: 28685846
  9. 9

    A man in his forties with increasing shortness of breath.

    Tveiten H, Lehne G, Aukrust P, et al.

    Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke 2020; (140(6)) doi:10.4045/tidsskr.19.0692.

    PMID: 32321231
  10. 10

    How I treat early-relapsing follicular lymphoma.

    Casulo C, Barr PM

    Blood 2019; (133(14)):1540-1547 doi:10.1182/blood-2018-08-822148.

    PMID: 30700421
  11. 11

    Bendamustine Plus Rituximab as Salvage Treatment for Patients with Relapsed or Refractory Low-grade B-cell Lymphoma and Mantle Cell Lymphoma: A Single-Center Retrospective Study.

    Murakami H, Yoshioka T, Moriyama T, et al.

    Acta medica Okayama 2021; (75(4)):461-469 doi:10.18926/AMO/62398.

    PMID: 34511613
  12. 12

    [Bendamustine and rituximab combination therapy for recurrent indolent B-cell lymphomas: a retrospective single-institution study].

    Teramoto M, Sone T, Takada K, et al.

    [Rinsho ketsueki] The Japanese journal of clinical hematology 2020; (61(6)):598-604 doi:10.11406/rinketsu.61.598.

    PMID: 32624531
  13. 13

    Therapy-related myeloid neoplasms in lymphoma survivors: Reducing risks.

    Al-Juhaishi T, Khurana A, Shafer D

    Best practice & research. Clinical haematology 2019; (32(1)):47-53 doi:10.1016/j.beha.2019.02.008.

    PMID: 30927975
  14. 14

    Myeloid neoplasms after CD19-directed CAR T cells therapy in long-term B-cell lymphoma responders, a rising risk over time?

    Gazeau N, Beauvais D, Tilmont R, et al.

    Leukemia 2025; (39(7)):1714-1722 doi:10.1038/s41375-025-02605-7.

    PMID: 40275069
  15. 15

    Therapy-related acute myeloid leukemia in patients with lymphoma: A report of four cases and review of the literature.

    Yang D, Fu X, Zhang X, et al.

    Oncology letters 2015; (10(5)):3261-3265 doi:10.3892/ol.2015.3703.

    PMID: 26722322
  16. 16

    Allogeneic hematopoietic stem cell transplantation for therapy-related myeloid neoplasms following treatment of a lymphoid malignancy.

    Wenge DV, Wethmar K, Mikesch JH, et al.

    Leukemia & lymphoma 2021; (62(8)):1930-1939 doi:10.1080/10428194.2021.1894645.

    PMID: 33779471
  17. 17

    Severe Late-Onset Neutropenia in a Pregnant Patient with Multiple Sclerosis after Ocrelizumab.

    Fealko CJ, Rolon-Newton MN, Aitken MJL, Gitlin SD

    Case reports in neurology 2025; (17(1)):36-40 doi:10.1159/000544749.

    PMID: 40292041
  18. 18

    Hypogammaglobulinemia, late-onset neutropenia, and infections following rituximab.

    Athni TS, Barmettler S

    Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology 2023; (130(6)):699-712 doi:10.1016/j.anai.2023.01.018.

    PMID: 36706910
  19. 19

    Impact of fear of cancer recurrence on survival among lymphoma patients.

    Kim SJ, Kang D, Kim IR, et al.

    Psycho-oncology 2020; (29(2)):364-372 doi:10.1002/pon.5265.

    PMID: 31654534
  20. 20

    Fear of Cancer Recurrence: A Systematic Review of Randomized, Controlled Trials.

    Chen D, Sun W, Liu N, et al.

    Oncology nursing forum 2018; (45(6)):703-712 doi:10.1188/18.ONF.703-712.

    PMID: 30339145
  21. 21

    Therapeutic intervention in fear of cancer recurrence in adult oncology patients: a systematic review.

    Paperák P, Javůrková A, Raudenská J

    Journal of cancer survivorship : research and practice 2023; (17(4)):1017-1035 doi:10.1007/s11764-022-01277-x.

    PMID: 36307611
  22. 22

    Acceptance and commitment therapy effectiveness for fear of cancer recurrence: A systematic review and meta-analysis.

    Yuyan Y, Jiaqi L, Ting W, et al.

    European journal of oncology nursing : the official journal of European Oncology Nursing Society 2025; (76()):102862 doi:10.1016/j.ejon.2025.102862.

    PMID: 40120332
  23. 23

    Acceptance and commitment therapy for breast cancer survivors with fear of cancer recurrence: A 3-arm pilot randomized controlled trial.

    Johns SA, Stutz PV, Talib TL, et al.

    Cancer 2020; (126(1)):211-218 doi:10.1002/cncr.32518.

    PMID: 31539169
  24. 24

    Psychometric evaluation of the Fear of Cancer Recurrence Inventory (FCRI) and development of a short version in patients with follicular lymphoma.

    Xu RH, Yu S, Yang Y, et al.

    Disability and rehabilitation 2022; (44(24)):7508-7515 doi:10.1080/09638288.2021.1985631.

    PMID: 34623949

This page provides information on follicular lymphoma survivorship and monitoring for educational purposes only. Always consult your oncology team for your specific follow-up care plan and medical advice.

Stay up to date

Get notified when new research about Follicular lymphoma is published.

No spam. Unsubscribe anytime.